Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Trauner

Showing results (731-740 of 777) with videos related to

Pageof 78
Sort By:
Nature Reviews. Gastroenterology & Hepatology|April 21, 2016
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)Jesus M Banales, Vincenzo Cardinale, Guido Carpino, et al.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
Journal of Hepatology|July 9, 2021
24-Norursodeoxycholic acid reshapes immunometabolism in CD8<sup>+</sup> T cells and alleviates hepatic inflammationCi Zhu, Nicole Boucheron, André C Müller, et al.
Wiener Klinische Wochenschrift|June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Journal of Hepatology|December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver diseaseGeorg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Metabolism: Clinical and Experimental|April 9, 2025
Leptin acutely increases hepatic triglyceride secretion in patients with lipodystrophyMarianna Beghini, Matthäus Metz, Clemens Baumgartner, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Journal of Hepatology|April 19, 2021
Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitisMaria Reich, Lina Spomer, Caroline Klindt, et al.
Pageof 78

Showing results (731-740 of 777) with videos related to

Sort By:
Pageof 78
Nature Reviews. Gastroenterology & Hepatology|April 21, 2016
Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)Jesus M Banales, Vincenzo Cardinale, Guido Carpino, et al.
Hepatology (Baltimore, Md.)|July 5, 2019
Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR TrialsQuentin M Anstee, Eric J Lawitz, Naim Alkhouri, et al.
Journal of Hepatology|July 9, 2021
24-Norursodeoxycholic acid reshapes immunometabolism in CD8<sup>+</sup> T cells and alleviates hepatic inflammationCi Zhu, Nicole Boucheron, André C Müller, et al.
Wiener Klinische Wochenschrift|June 26, 2023
Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)Mattias Mandorfer, Elmar Aigner, Manfred Cejna, et al.
Journal of Hepatology|December 6, 2021
HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver diseaseGeorg Semmler, Elias Laurin Meyer, Karin Kozbial, et al.
Journal of Hepatology|March 10, 2020
Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trialsStephen A Harrison, Vincent Wai-Sun Wong, Takeshi Okanoue, et al.
The Lancet. Gastroenterology & Hepatology|October 31, 2025
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trialMichael Trauner, Cynthia Levy, Atsushi Tanaka, et al.
Metabolism: Clinical and Experimental|April 9, 2025
Leptin acutely increases hepatic triglyceride secretion in patients with lipodystrophyMarianna Beghini, Matthäus Metz, Clemens Baumgartner, et al.
Annals of the Rheumatic Diseases|November 7, 2020
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statementPeter Nash, Andreas Kerschbaumer, Thomas Dörner, et al.
Journal of Hepatology|April 19, 2021
Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitisMaria Reich, Lina Spomer, Caroline Klindt, et al.
Pageof 78